

GILEAD TENOFOVIR LITIGATION

MTMP LAS VEGAS

October 14, 2022

Adam J. Gomez
Grant & Eisenhofer P.A.
agomez@gelaw.com



Tenofovir Disoproxil Fumarate

“TDF”

ATRIPLA[®]
(efavirenz 600 mg/emtricitabine 200 mg/
tenofovir disoproxil fumarate 300 mg) Tablets


Truvada[®]
200 mg emtricitabine · tenofovir disoproxil fumarate 300 mg


COMPLERA[®]
emtricitabine 200mg/rilpivirine 25mg/
tenofovir disoproxil fumarate 300mg tablets

STRIBILD[®] 
elvitegravir 150mg/ cobicistat 150mg/ emtricitabine
200mg/ tenofovir disoproxil fumarate 300mg tablets

viread[®]
(tenofovir disoproxil fumarate) 300 mg

Tenofovir
Alafenamide
Fumarate

“TAF”




Kidney Injuries



- Chronic Kidney Disease
- End Stage Renal Disease/Dialysis
- Fanconi Syndrome/
Renal Tubule Damage

Bone Injuries



- Osteopenia/Loss of Bone Mineral Density
 - with associated harm such as fracture or tooth loss
 - Osteoporosis
 - Osteomalacia
 - (Not Arthritis cases)

Litigation Status

California JCCP No. 5043



The Honorable Andrew Y.S. Cheng

- Coordinated in August 2019
- Assigned to Judge Cheng in September 2019
- **TRIAL DATE January 23, 2023**
- **Writ of Mandate Pending First DCA**